Cellular consequences, citrullination substrates, and antigenicity resulting from wild-type and targeted PAD4 on cell surfaces
Protein arginine deiminase-4 (PAD4) catalyzes hydrolysis of arginine to citrulline in proteins that promotes widespread changes in cellular phenotypes through transcriptional regulation that can induce innate immunity and promote cancer. Overexpression and hyperactivity of PAD4 leads to a form of cell death called NETosis that releases PAD4 to the extracellular space. In excess, release of PAD4 is believed to be a major cause of various autoimmune diseases through the generation of anti-citrulline protein antibodies (ACPAs). Little is known about the specific protein substrates that become citrullinated and lead to autoimmunity, but there is growing evidence that PAD4 can be localized to the cell surface in response to inflammation. Here, we further characterize the cellular consequences for exogenous treatment with PAD4 showing that it induces morphological changes that increase cell migration, a hallmark of cancer. We then devised a more simplified and robust proteomics approach to identify PAD4 substrates. We identified some 1000 endogenously citrullinated peptides from 500 proteins, and 3000 citrullinated peptides from 1300 proteins upon exogenous addition of PAD4 both inside and outside of cells. This extracellular set can be further augmented by targeting PAD4 to a cancer target, HER2, using a binding protein conjugate. Finally, we studied how citrullinated cells can induce a robust humoral response in a syngeneic vaccine model to produce ACPAs. We believe these studies further our understanding of cell phenotypic consequences of extracellular PAD4 and new PAD4 substrates both inside and outside of cells that are potential neoepitopes for generation of ACPAs.
Authors
- Sophie Kong (ORCID: https://orcid.org/0000-0002-2772-248X)
- Veronica Steri (ORCID: https://orcid.org/0000-0003-2499-6618)
- Paul Phojanakong
- James A. Wells (ORCID: https://orcid.org/0000-0001-8267-5519)
- Trenton M. Peters-Clarke (ORCID: https://orcid.org/0000-0002-9153-2525)
- Corleone S. Delaveris (ORCID: https://orcid.org/0000-0002-7291-2338)
Institutions
- University of California, San Francisco (US)
- Rapt Therapeutics (United States) (US)
- San Mateo Medical Center (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-01-06
- DOI
- https://doi.org/10.64898/2026.01.05.696859
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- A.P. Giannini Foundation
- Bristol-Myers Squibb
- Giannini Foundation of Agricultural Economics
- National Institutes of Health
- National Cancer Institute